Research Report University Hospital clinical trial 101MS326

Abstract

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension

Keywords

• Progressive Multiple Sclerosis
• natalizumab